KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-80 lat, każda płeć
- •Diagnoza białaczki limfoblastycznej B (B-ALL) z nawrotem lub opornością na leczenie
- •Potwierdzenie komórek białaczki CD19-dodatnich w szpiku lub krwi obwodowej
- •Wystarczająca funkcja wątroby, nerek, płuc i serca
- •Liczba limfocytów w krwi minimum 100/μL
- •Oczekiwana długość przeżycia ponad 3 miesiące
- •Dobry stan ogólny (zdolność do samoopieki)
- •Dobrowolna zgoda pacjenta lub jego reprezentanta prawnego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
First Affiliated Hospital of Zhejiang University
Hangzhou, China
Trial contact
He Huang, MD
Yongxian Hu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.